methyl 2- (2- acetoxy- 6,7- dihydrothieno(3,2- c)pyridin- 5(4H)- yl)- 2- (2- chlorophenyl)acetate

structure in first source

Also Known As:

vicagrel

Networked: 8 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylacetates: 3
      - methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate: 8
- Sulfur Compounds: 278
  - Thiophenes: 257
    - methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate: 8
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate: 8

Experts

1.	Gong, Yanchun: 4 articles (12/2022 - 01/2018)
2.	Lai, Xiaojuan: 4 articles (12/2022 - 01/2018)
3.	Li, Yongguo: 4 articles (12/2022 - 01/2018)
4.	Liu, Yongqiang: 4 articles (12/2022 - 01/2018)
5.	Sun, Hongbin: 4 articles (12/2022 - 01/2018)
6.	Liu, Cai: 3 articles (01/2019 - 01/2018)
7.	Liu, Xuefang: 3 articles (01/2019 - 01/2018)
8.	Yang, Jin: 3 articles (01/2019 - 01/2018)
9.	Zhang, Yifan: 3 articles (01/2019 - 01/2018)
10.	Zhong, Dafang: 3 articles (01/2019 - 01/2018)

Related Diseases

1.	Thrombosis (Thrombus) 07/01/2019 - "In the rat thrombus formation model, vicagrel (1 mg/kg) enhanced inhibition of thrombosis formation by aspirin (5 mg/kg), but not vice versa. " 07/01/2019 - "Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation." 07/01/2019 - "We conclude that vicagrel increases platelet responses to aspirin and also enhances inhibition of thrombus formation of aspirin due to decreased CES2-catalyzed aspirin inactivation in rodents, and that an integrated net effect on thrombus formation in vivo is superior to inhibition of AA- or ADP-induced platelet aggregation ex vivo by either of the two drugs if taken concomitantly."
2.	Acute Coronary Syndrome 09/01/2021 - "Vicagrel, a novel irreversible P2Y12 receptor inhibitor, is undergoing phase III trials for the treatment of acute coronary syndromes in China. " 02/05/2018 - "Vicagrel, an analog of clopidogrel, is a novel thienopyridine P2Y12 antagonist in clinical development in China for the treatment of acute coronary syndromes. " 10/01/2022 - "This study aimed to develop a semi-mechanistic population pharmacokinetic (PopPK) model to characterize the pharmacokinetic (PK) profile of M15-2, the active metabolite of vicagrel and clopidogrel, and to evaluate the influence of CYP2C19 polymorphisms and other covariates in healthy subjects and patients with acute coronary syndrome (ACS) after oral administration. " 01/15/2019 - "Vicagrel, a novel thienopyridine antiplatelet agent, is an analogue of clopidogrel in development for the treatment of acute coronary syndromes. "
3.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2018 - "Conclusion: Oral vicagrel demonstrated a favorable safety profile and excellent anti-platelet activity, which could be a promising P2Y12 antagonist as anti-platelet drug and can be further developed in phase II/III studies, and marketing for the unmet medical needs of cardiovascular diseases. " 01/01/2020 - "Simulations indicated that genetic polymorphisms and drug-drug interactions showed no clinical relevance for vicagrel, suggesting its potential advantages over clopidogrel for treatment of cardiovascular diseases. "
4.	Myocardial Infarction 12/02/2022 - "Two hundred and seventy-nine patients diagnosed with stable CAD (51.97%), unstable angina (40.86%), and myocardial infarction (7.17%) were randomized to receive vicagrel 20/5 mg (LD/MD), 24/6 mg, or 30/7.5 mg or clopidogrel 300/75 mg in combination with aspirin. "
5.	Hemorrhage 12/02/2022 - "There were no significant differences in AEs (4.35%, 0%, 1.45%, and 5.56% for vicagrel 20/5, 24/6, and 30/7.5 mg and clopidogrel, P = 0.6667) or any bleeding (13.04%, 14.06%, 11.59%, and 11.11% for vicagrel 20/5, 24/6, and 30/7.5 mg and clopidogrel, respectively, P = 0.95) across four groups. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Adenosine Diphosphate (ADP)
3.	Clopidogrel (Plavix)
4.	Cytochrome P-450 CYP2C19
5.	thienopyridine
6.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)

Related Therapies and Procedures

1.	Oral Administration
2.	Percutaneous Coronary Intervention